Anaptysbio Inc (ANAB) Stock Price, Quote & News

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared co...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 362 6295

Website: www.anaptysbio.com

Address:

10770 Wateridge Circle, Suite 210, San Diego, United States

fortmort22 Aug. 7 at 7:22 PM

$ANAB robbed in broad

1 · Reply

Tradingonthepan Aug. 7 at 7:04 PM

$ANAB wow. Well that’ll be that then..

0 · Reply

Sky360 Aug. 7 at 6:27 PM

$ANAB Why does every time this stock gets a price target upgrade it drops like a rock?

1 · Reply

fortmort22 Aug. 7 at 4:52 PM

$ANAB what is happening here....

1 · Reply

Sky360 Aug. 7 at 2:22 PM

$ANAB 🚀🚀🚀

0 · Reply

hen_lewis Aug. 7 at 1:45 PM

$ANAB super high short %, earnings beat, insane analyst targets. Yet still red

1 · Reply

JarvisFlow Aug. 7 at 1:00 PM

Wedbush has updated their rating for AnaptysBio ( $ANAB ) to Outperform with a price target of 45.

1 · Reply

BravoDelta Aug. 7 at 5:26 AM

$ANAB Positive reading $42 📈

1 · Reply

hbwalk2 Aug. 6 at 9:27 PM

$ANAB Earnings summary seems quite encouraging. GSK should just buy them instead of paying milestones and royalties.

1 · Reply

Mbuck17 Aug. 6 at 8:28 PM

$ANAB https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-second-quarter-2025-financial-results-and

1 · Reply

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 1:33 PM EDT - 2 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 6, 2025, 3:39 PM EDT - 2 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 4, 2025, 2:23 PM EDT - 2 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 3, 2025, 4:05 PM EDT - 2 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

May 27, 2025, 4:15 PM EDT - 2 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 5, 2025, 4:15 PM EDT - 3 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Mar 24, 2025, 9:15 AM EDT - 4 months ago

Anaptys Announces Stock Repurchase Plan

Feb 27, 2025, 4:15 PM EST - 5 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 5 months ago

Anaptys Announces Participation in March Investor Conferences

Feb 12, 2025, 7:30 AM EST - 6 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 11, 2025, 5:30 PM EST - 6 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 3, 2025, 4:15 PM EST - 6 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 7:30 AM EST - 6 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Jan 7, 2025, 9:15 AM EST - 7 months ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 2:07 PM EST - 8 months ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 10:20 AM EST - 8 months ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 8 months ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:30 AM EST - 8 months ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Nov 5, 2024, 4:15 PM EST - 9 months ago

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 9 months ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Aug 29, 2024, 9:15 AM EDT - 1 year ago

Anaptys Announces Participation in September Investor Conferences

Aug 15, 2024, 2:14 PM EDT - 1 year ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 14, 2024, 5:00 AM EDT - 1 year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 5, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 2:53 PM EDT - 1 year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

May 9, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:05 PM EDT - 1 year ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA

Mar 11, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Jan 31, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Nov 27, 2023, 4:15 PM EST - 1 year ago

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Nov 7, 2023, 4:15 PM EST - 1 year ago

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Nov 2, 2023, 4:15 PM EDT - 1 year ago

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 9:15 AM EDT - 1 year ago

Anaptys Announces Participation in November Investor Conferences

Oct 11, 2023, 9:15 AM EDT - 1 year ago

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Oct 9, 2023, 8:32 AM EDT - 1 year ago

AnaptysBio's skin disease drug meets main goal in late-stage study

Oct 9, 2023, 8:15 AM EDT - 1 year ago

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Oct 9, 2023, 8:00 AM EDT - 1 year ago

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Sep 18, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

Sep 12, 2023, 9:15 AM EDT - 2 years ago

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

Aug 7, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 31, 2023, 1:34 PM EDT - 2 years ago

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Jul 7, 2023, 10:33 AM EDT - 2 years ago

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

May 30, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Participation in Upcoming Investor Conferences

May 11, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

May 2, 2023, 9:15 AM EDT - 2 years ago

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Apr 6, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

fortmort22 Aug. 7 at 7:22 PM

$ANAB robbed in broad

1 · Reply

Tradingonthepan Aug. 7 at 7:04 PM

$ANAB wow. Well that’ll be that then..

0 · Reply

Sky360 Aug. 7 at 6:27 PM

$ANAB Why does every time this stock gets a price target upgrade it drops like a rock?

1 · Reply

fortmort22 Aug. 7 at 4:52 PM

$ANAB what is happening here....

1 · Reply

Sky360 Aug. 7 at 2:22 PM

$ANAB 🚀🚀🚀

0 · Reply

hen_lewis Aug. 7 at 1:45 PM

$ANAB super high short %, earnings beat, insane analyst targets. Yet still red

1 · Reply

JarvisFlow Aug. 7 at 1:00 PM

Wedbush has updated their rating for AnaptysBio ( $ANAB ) to Outperform with a price target of 45.

1 · Reply

BravoDelta Aug. 7 at 5:26 AM

$ANAB Positive reading $42 📈

1 · Reply

hbwalk2 Aug. 6 at 9:27 PM

$ANAB Earnings summary seems quite encouraging. GSK should just buy them instead of paying milestones and royalties.

1 · Reply

Mbuck17 Aug. 6 at 8:28 PM

$ANAB https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-second-quarter-2025-financial-results-and

1 · Reply

Tradingonthepan Aug. 5 at 1:35 PM

$ANAB 😑

1 · Reply

JillianKillcannon Aug. 5 at 1:05 AM

$ANAB so…we flyin tomorrow? Surprise revenue is a giant bull flag right?

2 · Reply

LongBomb Aug. 4 at 5:09 PM

$ANAB Shares held by tutes is still at 124.06%. We'll see what that portends but some people don't understand...

0 · Reply

Tradingonthepan Aug. 4 at 2:00 PM

$ANAB Earnings better be good. High price targets with continued institutional buying and the sp is like na

1 · Reply

Bbboston Aug. 4 at 1:18 PM

$ANAB How is it that 57% of the float is short? 130% owned by institutions!! I never understood this phenomenon.

1 · Reply

Sky360 Jul. 31 at 2:15 PM

$ANAB

0 · Reply

Sky360 Jul. 31 at 2:14 PM

$ANAB last chance at a discount! Next week this thing is going to fly. 🚀🚀🚀

1 · Reply

Stockwitts123 Jul. 30 at 8:39 PM

$GRRR Not sure if I listen to bots?! This guy has hundreds or probably thousands of posts just today pumping $ANAB

1 · Reply

TheSlimTrader Jul. 30 at 3:23 PM

$ANAB the cleared out stops. Look at the volume today. Already well past last few days. They are loading and covering. I added calls and shares at the bottom when rsi was 0.7

0 · Reply

LongBomb Jul. 30 at 2:26 PM

$ANAB Looks like it. 123% owned by tutes and over 31% short interest. As a retail dummy, I'll hang on to my shares and see what happens.

2 · Reply

TheSlimTrader Jul. 30 at 2:20 PM

$ANAB well I think they just cleared out retail.

0 · Reply

Tradingonthepan Jul. 30 at 2:07 PM

$ANAB lmao

0 · Reply

Market Cap	696.01M
Revenue (ttm)	91.28M
Net Income (ttm)	-145.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-159.10%
Debt to Equity Ratio	0.00

Volume	529,200
Avg Vol	605,766
Day's Range	N/A - N/A
Shares Out	29.38M
Stochastic %K	5%
Beta	-0.20
Analysts	Strong Sell
Price Target	$49.00